Medicamen Biotech Limited
NSE: MEDICAMEQ · Pharmaceuticals · sector
₹263.00NSE close 2026-10-26
Key numbers
Market cap₹357 cr
Price₹263.00
52w high / low₹448 / ₹212
P/E35.5xSector median 27.9x
P/B1.3xSector median 2.9x
Book value₹203.2
Dividend yield0.38%Sector median 0.48%
ROE4.4%Sector median 11.7%
ROCE4.8%Sector median 12.3%
OPM9.5%Sector median 14.0%
Debt / equity0.17xSector median 0.16x
EV/EBITDA19.2xSector median 18.6x
Interest cover4.9x
Current ratio2.54x
Sales growth 3y+12.0%Sector median +9.6%
Profit growth 3y-13.4%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹34 cr vs borrowings ₹48 cr (FY26): borrowings are higher by ₹14 cr.
- Borrowings rose in each of the last 3 years (₹24 cr → ₹48 cr).
- Operating profit covered interest 4.9x in the last 12 months.
- Operating cash flow was below net profit in 5 of the last 5 years (FY26, FY25, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 32% of net profit in the last 12 months.
- Debtor days went from 112 (FY24) to 151 (FY26).
- Dividend paid in 4 of the last 5 financial years.
- Price ₹263.00 on 2026-10-26: -41.2% from the 52-week high, +23.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹579.60 · low ₹227.80
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45 | 45 | 30 | 43 | 47 | 47 | 61 | 48 |
| EBITDA | 5 | 7 | -2 | 5 | 5 | 4 | 5 | 4 |
| OPM % | 11.9% | 14.9% | -5.4% | 10.7% | 10.9% | 9.3% | 9.0% | 9.0% |
| Other income | 0 | 0 | 5 | 0 | 0 | 1 | 2 | 1 |
| Net profit | 1 | 3 | 2 | 2 | 3 | 2 | 4 | 2 |
| EPS (₹) | 0.71 | 2.30 | 1.47 | 1.18 | 1.56 | 1.21 | 3.28 | 1.36 |
| Revenue YoY | +5.4% | +3.9% | +104.8% | +11.3% | ||||
| Profit YoY | +82.9% | -25.0% | +59.5% | -1.4% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 115 | 141 | 179 | 163 | 198 | 203 |
| EBITDA | 24 | 24 | 22 | 14 | 20 | 19 |
| Net profit | 15 | 15 | 11 | 7 | 10 | 11 |
| EPS (₹) | 12.19 | 11.82 | 7.50 | 5.16 | 7.22 | 7.41 |
| Revenue growth | +22.0% | +27.3% | -9.3% | +21.7% | +24.7% | |
| Profit growth | -0.4% | -26.3% | -34.9% | +35.6% | +21.0% | |
| Dividend / share (₹) | – | 1.00 | 1.00 | 1.00 | 1.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +12.0% | – | +24.7% |
| Net profit | -13.4% | – | +21.0% |
| EPS | -15.2% | – | – |
| Share price | – | -26.1% (2y) | -18.9% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 193 | 200 | 213 | 276 |
| Borrowings | – | 24 | 31 | 33 | 48 |
| Cash & equivalents | – | 21 | 15 | 4 | 34 |
| Total assets | – | 279 | 295 | 297 | 372 |
| Fixed assets | – | 92 | 91 | 86 | 84 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 65 | 55 | 69 | 82 |
| Inventory | – | 45 | 59 | 62 | 70 |
| Payables | – | 48 | 45 | 43 | 40 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 4 | -6 | -0 | -7 | -33 |
| Cash from investing | -8 | -6 | -6 | -2 | -3 |
| Cash from financing | 4 | 29 | -0 | -2 | 64 |
| Capex | 9 | 7 | 6 | 2 | 5 |
| Free cash flow | -4 | -13 | -7 | -9 | -38 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 7.7% | 5.5% | 3.3% | 3.5% |
| ROCE % | – | 9.2% | 7.6% | 5.3% | 4.8% |
| Debtor days | – | 169 | 112 | 155 | 151 |
| Inventory days | – | 228 | 234 | 268 | 251 |
| Payable days | – | 241 | 179 | 184 | 143 |
| Cash conversion cycle (days) | – | 156 | 167 | 239 | 259 |
| Working capital days | – | 209 | 140 | 194 | 251 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 40.46% |
| FIIs | 4.49% |
| DIIs | 0.00% |
| of which Mutual funds | 0.00% |
| Government | 0.05% |
| Public (non-institutions) | 55.00% |
| Quarter | Mar 2025 | Apr 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| Promoter group | % |
|---|---|
| Shivalik Rasayan Limited | 40.46% |
| Growel Remedies Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Pharmadanica A/S | 9.88% |
| Veralogix Holdings(pty) Ltd | 4.42% |
| Ginnerup Capital APS | 2.62% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.26% |
| Rajesh Madan | 1.14% |
| Vijay Amichand Sanghvi | 1.12% |
11,680 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MEDICAMEQ | ₹357 cr | 35.5x | 1.3x | 4.4% | 4.8% | 9.5% | +12.0% | 0.38% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-18 | Dividend | Dividend - Re 1 Per Share |
| 2025-09-19 | Dividend | Dividend - Re 1 Per Share |
| 2024-09-19 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2023-09-20 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
| 2022-09-19 | Dividend | Annual General Meeting/Dividend - Re 1 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Research & Development, Manufacturing, Marketing, and Distribution of Pharmaceutical Products: Medicamen Biotech Limited is engaged in the manufacturing and marketing of pharmaceutical formulations across various therapeutic segments. The Company manufactures tablets, capsules, dry syrups, oral liquids, ointments and other pharmaceutical dosage forms for domestic as well as international markets through its manufacturing facilities. The Company exports its products to more than 35 countries across Asia, Africa, Latin America and other international markets.
- Pharmaceutical R&D / formulation development: Providing consultancy and product validation services to a foreign company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MEDICAMEQ |
| BSE code | 531146 |
| ISIN | INE646B01010 |
| Face value | ₹10.0 |
| Incorporated | 1993-12-22 |
| Website | www.medicamen.com |
| Plants (India / abroad) | 3 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.